636-88-4

Basic information

• Product Name: (S)-(+)-NOREPINEPHRINE L-BITARTRATE
• Synonyms: (S)-(+)-NOREPINEPHRINE L-BITARTRATE;ALPHA-(AMINOMETHYL)-3,4-DIHYDROXYBENZYL ALCOHOL L-BITARTRATE;D-Norepinephrine hydrogen tartrate salt;(S)-beta,3,4-trihydroxyphenethylammonium [R-(R*,R*)]-hydrogen tartrate;D-Noradrenaline L-bitartrate, D-Noradrenaline hydrogen L-tartrate, D-Norepinephrine D-bitartrate, (+)-α-(Aminomethyl)-3,4-dihydroxybenzyl alcohol (+)-tartrate (1:1);D-Arterenol hydrogen tartrate salt, D-Noradrenaline hydrogen tartrate salt, D-Norepinephrine bitartrate;4-[(1S)-2-amino-1-hydroxyethyl]benzene-1,2-diol;4-[(1S)-2-amino-1-hydroxy-ethyl]pyrocatechol
• CAS NO: 636-88-4
• Molecular Formula: C₄H₆O₆*C₈H₁₁NO₃
• Molecular Weight: 469.35
• EINECS: 211-268-5
• Mol File: 636-88-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 166 °C (dec.)(lit.)
• Boiling Point: 442.6°C at 760 mmHg
• Flash Point: 221.5°C
• Appearance: /
• Vapor Pressure: 1.3E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-(+)-NOREPINEPHRINE L-BITARTRATE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-NOREPINEPHRINE L-BITARTRATE(636-88-4)
• EPA Substance Registry System: (S)-(+)-NOREPINEPHRINE L-BITARTRATE(636-88-4)

Safety Data

• Hazard Codes: T,Xn
• Statements: 25-36/37/38-20/21/22
• Safety Statements: 36/37-45-37/39-26
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• F: 8-10-23
• Hazardous Substances Data: 636-88-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H11NO3.C4H6O6/c9-4-8(12)5-1-2-6(10)7(11)3-5;5-1(3(7)8)2(6)4(9)10/h1-3,8,10-12H,4,9H2;1-2,5-6H,(H,7,8)(H,9,10)/t8-;1-,2-/m11/s1

Upstream product

• 99-40-1 2-chloro-3',4'-dihydroxyacetophenone 
• 87-69-4 L-Tartaric acid 

Downstream Products

• 1044185-27-4 (S)-N-Boc-noradrenaline 

Relevant articles and documents

A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE NOREPINEPHRINE

The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer. The invention also discloses a novel intermediate and the process for the preparation thereof.